There is no disease without a solution. Stem cells are quite a saviour for medical issues. They can develop into all the kinds of cells needed if given a proper environment. In tough times like now, one needs to have proper guidance and doctors. Stem plus Cryopreservation Pvt. Ltd is one of them!
Stem plus Cryopreservation Pvt. Ltd was started in the year 2012 and is headquatered in Sangli Miraj Kupwad Commercial Complex, C/S No. 1317/2, Near Shivaji Maharaj Putla, Bus Stand Road, Gaon Bhag, Sangli, MS – 416416, India. It was found with a commitment to make cord blood banking affordable for parents; without compromising the service and quality. The company is DCGI/FDA licensed and certified by cGLP with its ISO number as 9001:2008 by Australian company TCL. It is the first DCGI/FDA approved company in western Maharashtra.
The company maintains the highest possible cord blood standards in the industry. They are processed according to cGMP, DCGI, FACT, and AABB standards.
About the company
Stem plus Cryopreservation Pvt. Ltd gives hope and help to clients in need of stem cell transplant by cryopreservation of precious stem cells. It is committed to studying best ways to collect; process and store cord blood to improve transplant outcomes for clients and provides high quality services to the clients.
What makes Stem plus Cryopreservation Pvt. Ltd unique?
Stem Plus is first company to bank cord Blood stem cells and VSELS comparatively economical rates. It develops a level of trust and belief in the customers mind and then pitches to them. It focuses on the quality of customer base and the services provided instead of the quantity. Stem Plus Cryopreservation is the first company in the world to develop technology to bank urine-derived stem cells.
What are stem cells?
Stem cells, are the basic cells which have the capacity to develop into almost all types of cells of the body. If given correct environment and necessary stimulus, each stem cell can develop into an organ. Such is the power of these tiny living cells. These stem cells have opened a new avenue for therapeutics, which will give a total regenerative cure unlike preventive or curative treatment. Untreatable diseases with no known treatment modality available for muscular dystrophies, diabetes mellitus, parkinsonism, stroke, autism, hair loss have shown promising results after transplantation of stem cells.
The company was started by Dr Meghnad Joshi who is the CMD of the company. Dr Meghnad G Joshi did Ph.D. from department of Zoology, Shivaji University, Kolhapur, India in 2006. He Joined Karolinska Institute, Sweden as Postdoctoral fellow in 2007-2008 for fetal and adult hepatocyte transplantation studies. He worked for Sahlgrenska University Hospital, Department of transplantation surgery, Göteborg, Sweden from 2008-2010. In 2009, he was awarded with TTS New Key Opinion leader, Sweden. He has been appointed as a visiting Assistant professor by Kansas medical Center, USA since 2010 till 2012. He was a part of first tissue engineered tracheal transplant in Sahlgrenska University Hospital, Sweden. He has worked as the Lab director in StemOne Biologicals Pvt. Ltd from 2011-2012. Presently, he is working as Associate Professor and Head, Department of Stem cells and Regenerative medicine, D.Y. Patil University, Kolhapur and he has 2 ongoing projects in his lab and 6 Ph.D. students working under his guidance. He is CMD of stem Plus Cryopreservation Pvt. Ltd a DCGI/FDA approved cord blood bank in Sangli, Maharashtra, India. He is BOS member, Zoology, Shivaji University, Kolhapur. His area of research are stem cells, stem cell transplant, tissue engineering and 3D bioprinting. He has published more than 35 papers, 4 Book chapters and 5 patents.
Patents of the company
- “Synthesis process of composite artificial Skin Bioink for 3D Bioprinting and wound healing applications” 1st Feb 2019. The patent application number: 201921004686
- “Method of Constructing Tissue Engineered Human Ear Pinna Prosthesis” 1st Feb 2019. The patent application number: 201921004685
The company aims to scale up infrastructure needs for Public cord blood banking and expand stem cell services, Pan India (Main cellular facility Kolhapur). The company is also planning to invest in the R&D of stem cell products in the next 3 years.
The company works ethically, provides prompt service, safeguards the stakeholder’s interest and their trust, uses environment friendly technologies and cares for nature.
It also treats all its stakeholders with dignity, respect and love!